Search

Your search keyword '"Green, Damian"' showing total 319 results
Start Over Author "Green, Damian" Publication Type Academic Journals
319 results on '"Green, Damian"'

2. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity

Author

Bodansky, Aaron, Yu, David J.L., Rallistan, Alysa, Kalaycioglu, Muge, Boonyaratanakornki, Jim, Green, Damian J., Gauthier, Jordan, Turtle, Cameron J., Zorn, Kelsey, O'Donovan, Brian, Mandel-Brehm, Caleigh, Asaki, James, Kortbawi, Hannah, Kung, Andrew F., Rackaityte, Elze, Wang, Chung-Yu, Saxena, Aditi, de Dios, Kimberly, Masi, Gianvito, Nowak, Richard J., O'Connor, Kevin C., Li, Hao, Diaz, Valentina E., Saloner, Rowan, Casaletto, Kaitlin B., Gontrum, Eva Q., Chan, Brandon, Kramer, Joel H., Wilson, Michael R., Utz, Paul J., Hill, Joshua A., Jackson, Shaun W., Anderson, Mark S., and DeRisi, Joseph L.

Subjects
T cells -- Health aspects, Proteomics -- Analysis, Cellular therapy -- Complications and side effects -- Patient outcomes, Viral antibodies -- Health aspects, Antibodies -- Health aspects, Health care industry, Analysis, Complications and side effects, Patient outcomes, Health aspects
Abstract

Given the global surge in autoimmune diseases, it is critical to evaluate emerging therapeutic interventions. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches to apply and evaluate the effects of these treatments longitudinally are lacking. Here, we leveraged advances in programmable-phage immunoprecipitation methodology to explore the modulation, or lack thereof, of autoantibody profiles, proteome-wide, in both health and disease. Using a custom set of over 730,000 human-derived peptides, we demonstrated that each individual, regardless of disease state, possesses a distinct and complex constellation of autoreactive antibodies. For each individual, the set of resulting autoreactivites constituted a unique immunological fingerprint, or "autoreactome," that was remarkably stable over years. Using the autoreactome as a primary output, we evaluated the relative effectiveness of various immunomodulatory therapies in altering autoantibody repertoires. We found that therapies targeting B cell maturation antigen (BCMA) profoundly altered an individual's autoreactome, while anti-CD19 and anti-CD20 therapies had minimal effects. These data both confirm that the autoreactome comprises autoantibodies secreted by plasma cells and strongly suggest that BCMA or other plasma cell- targeting therapies may be highly effective in treating currently refractory autoantibody-mediated diseases., Introduction Autoantibodies have been identified in a wide range of autoimmune diseases (1-4). In many cases these autoantibodies are directly pathogenic (5-10), while in others they amplify or support T [...]

Published
2024
Full Text
View/download PDF

4. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

Author

Coffey, David G., Maura, Francesco, Gonzalez-Kozlova, Edgar, Diaz-Mejia, J. Javier, Luo, Ping, Zhang, Yong, Xu, Yuexin, Warren, Edus H., Dawson, Travis, Lee, Brian, Xie, Hui, Smith, Eric, Ciardiello, Amanda, Cho, Hearn J., Rahman, Adeeb, Kim-Schulze, Seunghee, Diamond, Benjamin, Lesokhin, Alexander, Kazandjian, Dickran, Pugh, Trevor J., Green, Damian J., Gnjatic, Sacha, and Landgren, Ola

Published
2023
Full Text
View/download PDF

6. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Hirayama, Alexandre V., Kimble, Erik L., Wright, Jocelyn H., Fiorenza, Salvatore, Gauthier, Jordan, Voutsinas, Jenna M., Wu, Qian, Yeung, Cecilia C. S., Gazeau, Nicolas, Pender, Barbara S., Kirchmeier, Delaney R., Torkelson, Aiko, Chutnik, Abigail N., Cassaday, Ryan D., Chapuis, Aude G., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2024
Full Text
View/download PDF

7. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Author

Gazeau, Nicolas, Liang, Emily C., Wu, Qian “Vicky”, Voutsinas, Jenna M., Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Ortega, Juan Luis Reguera, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Martínez-Cibrian, Nuria, Martinez, Antonio Perez, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Kimble, Erik, Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., and Gauthier, Jordan

Published
2023
Full Text
View/download PDF

8. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

Author

Cowan, Andrew J, Pont, Margot J, Sather, Blythe D, Turtle, Cameron J, Till, Brian G, Libby, Edward N, 3rd, Coffey, David G, Tuazon, Sherilyn A, Wood, Brent, Gooley, Ted, Wu, Vicky Q, Voutsinas, Jenna, Song, Xiaoling, Shadman, Mazyar, Gauthier, Jordan, Chapuis, Aude G, Milano, Filippo, Maloney, David G, Riddell, Stanley R, and Green, Damian J

Published
2023
Full Text
View/download PDF

9. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Author

Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, and Dhodapkar, Madhav

Subjects
Hematology, Immunization, Rare Diseases, Vaccine Related, Biotechnology, Cancer, Orphan Drug, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Consensus, Humans, Immunotherapy, Multiple Myeloma, guidelines as topic, immunotherapy, hematological neoplasms, receptors, chimeric antigen, antineoplastic protocols, receptors, chimeric antigen
Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Published
2020

13. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Author

Gauthier, Jordan, Bezerra, Evandro D., Hirayama, Alexandre V., Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K., Kimble, Erik L., Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Jamieson, Abby W., Bar, Merav, Cassaday, Ryan D., Chapuis, Aude G., Cowan, Andrew J., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2021
Full Text
View/download PDF

14. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Author

Holstein, Sarah A., Howard, Alan, Avigan, David, Bhutani, Manisha, Cohen, Adam D., Costa, Luciano J., Dhodapkar, Madhav V., Gay, Francesca, Gormley, Nicole, Green, Damian J., Hillengass, Jens, Korde, Neha, Li, Zihai, Mailankody, Sham, Neri, Paola, Parekh, Samir, Pasquini, Marcelo C., Puig, Noemi, Roodman, G. David, Samur, Mehmet Kemal, Shah, Nina, Shah, Urvi A., Shi, Qian, Spencer, Andrew, Suman, Vera J., Usmani, Saad Z., and McCarthy, Philip L.

Published
2020
Full Text
View/download PDF

15. 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

Author

Tuazon, Sherilyn A., Sandmaier, Brenda M., Gooley, Theodore A., Fisher, Darrell R., Holmberg, Leona A., Becker, Pamela S., Lundberg, Sally J., Orozco, Johnnie J., Gopal, Ajay K., Till, Brian G., Coffey, David G., Nartea, Margaret E., Matesan, Manuela C., Pagel, John M., Rajendran, Joseph G., Press, Oliver W., Bensinger, William I., and Green, Damian J.

Published
2021
Full Text
View/download PDF

17. Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Author

Kampouri, Eleftheria, Krantz, Elizabeth M., Xie, Hu, Ibrahimi, Sarah S., Kiem, Erika S., Sekhon, Mandeep K., Liang, Emily C., Cowan, Andrew J., Portuguese, Andrew, Green, Damian J., Albittar, Aya, Huang, Jennifer J., Gauthier, Jordan, Pérez-Osorio, Ailyn C., Jerome, Keith R., Zerr, Danielle M., Boeckh, Michael J., and Hill, Joshua A.

Published
2024
Full Text
View/download PDF

19. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.

Author

Kampouri, Eleftheria, Ibrahimi, Sarah S, Xie, Hu, Wong, Elizabeth R, Hecht, Jessica B, Sekhon, Mandeep K, Vo, Alythia, Stevens-Ayers, Terry L, Green, Damian J, Gauthier, Jordan, Maloney, David G, Perez, Ailyn, Jerome, Keith R, Leisenring, Wendy M, Boeckh, Michael J, and Hill, Joshua A

Subjects
RISK assessment, ADRENOCORTICAL hormones, CYTOPENIA, VIRAL load, RECEIVER operating characteristic curves, RESEARCH funding, CYTOMEGALOVIRUS diseases, IMMUNOTHERAPY, CELLULAR immunity, TREATMENT effectiveness, DESCRIPTIVE statistics, REINFECTION, ANTIGENS, LONGITUDINAL method, PRE-tests & post-tests, INTERFERONS, CONFIDENCE intervals, REGULATORY T cells, CELL receptors, REGRESSION analysis, DISEASE risk factors
Abstract

Background The epidemiology of cytomegalovirus (CMV) after chimeric antigen receptor–modified T-cell immunotherapy (CARTx) is poorly understood owing to a lack of routine surveillance. Methods We prospectively enrolled 72 adult CMV-seropositive CD19-, CD20-, or BCMA-targeted CARTx recipients and tested plasma samples for CMV before and weekly up to 12 weeks after CARTx. We assessed CMV-specific cell-mediated immunity (CMV-CMI) before and 2 and 4 weeks after CARTx, using an interferon γ release assay to quantify T-cell responses to IE-1 and pp65. We tested pre-CARTx samples to calculate a risk score for cytopenias and infection (CAR-HEMATOTOX). We used Cox regression to evaluate CMV risk factors and evaluated the predictive performance of CMV-CMI for CMV reactivation in receiver operator characteristic curves. Results CMV was detected in 1 patient (1.4%) before and in 18 (25%) after CARTx, for a cumulative incidence of 27% (95% confidence interval, 16.8–38.2). The median CMV viral load (interquartile range) was 127 (interquartile range, 61–276) IU/mL, with no end-organ disease observed; 5 patients received preemptive therapy based on clinical results. CMV-CMI values reached a nadir 2 weeks after infusion and recovered to baseline levels by week 4. In adjusted models, BCMA-CARTx (vs CD19/CD20) and corticosteroid use for >3 days were significantly associated with CMV reactivation, and possible associations were detected for lower week 2 CMV-CMI and more prior antitumor regimens. The cumulative incidence of CMV reactivation almost doubled when stratified by BCMA-CARTx target and use of corticosteroids for >3 days (46% and 49%, respectively). Conclusions CMV testing could be considered between 2 and 6 weeks in high-risk CARTx recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies.

Author

Minnie, Simone A., Waltner, Olivia G., Zhang, Ping, Takahashi, Shuichiro, Nemychenkov, Nicole S., Ensbey, Kathleen S., Schmidt, Christine R., Legg, Samuel R. W., Comstock, Melissa, Boiko, Julie R., Nelson, Ethan, Bhise, Shruti S., Wilkens, Alec B., Koyama, Motoko, Dhodapkar, Madhav V., Chesi, Marta, Riddell, Stanley R., Green, Damian J., Spencer, Andrew, and Furlan, Scott N.

Subjects
T-cell exhaustion, HEMATOLOGIC malignancies, BONE marrow cancer, CHIMERIC antigen receptors, PHENOTYPES
Abstract

Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (TPHEX), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ+ TPHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ+ TPHEX. We also observed IFN-γ+ TPHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19+ leukemia cells. An IFN-γ+ TPHEX gene signature was recapitulated in TEX cells from human cancers, including myeloma and lymphoma. Here, we characterize a TEX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional TEX found in chronic viral infections. Thus, IFN-γ+ TPHEX represent a potential target for immunotherapy of blood cancers. Editor's Summary: Chronic antigen stimulation can drive CD8 T cell exhaustion and dysfunction among multiple T cell subsets. Using a murine myeloma model, Minnie et al. characterized a terminally exhausted CD8 T cell subset in the bone marrow tumor microenvironment that expressed not only transcription and epigenetic factors associated with exhaustion but also effector molecules, including IFN-γ, granzymes, and perforin. This subset, IFN-γ+ TPHEX (IFN-γ–secreting, phenotypically exhausted T cells), could kill myeloma cells, and IFN-γ+ TPHEX differentiated from CD19-targeted chimeric antigen receptor T cells could kill CD19+ tumor cells. An analogous IFN-γ+ TPHEX subset was also detected in patients with myeloma and lymphoma. Together, these findings suggest that IFN-γ+ TPHEX have dysfunctional features but retain functionality, facilitating antitumor responses. —Christiana Fogg [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy.

Author

Treger, Rebecca S, Mathias, Patrick C, Cowan, Andrew J, Green, Damian, Hutchinson, Kathleen, Bryan, Andrew, Chaudhary, Anu, Fink, Susan L, Wener, Mark H, and Morishima, Chihiro

Subjects
IMMUNOGLOBULIN light chains, MONOCLONAL antibodies, MONOCLONAL gammopathies, KIDNEY physiology, NOSOLOGY, KIDNEYS, IMMUNE serums
Abstract

Objectives To evaluate the real-world performance and reference intervals of the Binding Site Freelite serum free light chain (SFLC) assay (Thermo Fisher Scientific), a global standard for diagnosis, prognostication, and response assessment for monoclonal gammopathies. Methods An informatics-based approach was used to retrospectively evaluate concordance between SFLC and the orthogonal Sebia HYDRASYS immunofixation assay results in a large clinical data set consecutively reported between 2010 and 2020. Results Among patients with monoclonal-negative results by both SFLC and Sebia HYDRASYS immunofixation assays, 25% (1226/5057) had κ/λ ratios (KLRs) outside the manufacturer-defined and International Myeloma Working Group–cited normal reference interval of 0.26 to 1.65. These results were consistent over the study period and were not affected by sex, age, impaired kidney function, or assay antisera lot variation. Assay drift, in addition to other potential factors, affected the KLR distribution. Using International Statistical Classification of Diseases (ICD) codes, kidney function data, and the central 95% of KLR values generated on the Optilite platform (Thermo Fisher Scientific), we derived a new reference interval of 0.67 to 2.13, reducing the KLR false-positive rate to 8%. However, normal KLR persisted among 16% (14/85) of samples with free λ chains by immunofixation, warranting caution during interpretation. Conclusions Our analysis indicated that revision of Freelite SFLC reference intervals improves assay interpretation and should prompt reconsideration of Freelite reference intervals worldwide. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

Author

Tuazon, Sherilyn A., Cassaday, Ryan D., Gooley, Theodore A., Sandmaier, Brenda M., Holmberg, Leona A., Smith, Stephen D., Maloney, David G., Till, Brian G., Martin, Daniel B., Chow, Victor A., Rajendran, Joseph G., Fisher, Darrell R., Matesan, Manuela C., Lundberg, Sally J., Green, Damian J., Pagel, John M., Press, Oliver W., and Gopal, Ajay K.

Published
2021
Full Text
View/download PDF

30. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Author

Cowan, Andrew J., Stevenson, Philip A., Cassaday, Ryan D., Graf, Solomon A., Fromm, Jonathan R., Wu, David, Holmberg, Leona A., Till, Brian G., Chauncey, Thomas R., Smith, Stephen D., Philip, Mary, Orozco, Johnnie J., Shustov, Andrei R., Green, Damian J., Libby, Edward N., III, Bensinger, William I., Shadman, Mazyar, Maloney, David G., Press, Oliver W., and Gopal, Ajay K.

Published
2016
Full Text
View/download PDF

33. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model

Author

Green, Damian J., Shadman, Mazyar, Jones, Jon C., Frayo, Shani L., Kenoyer, Aimee L., Hylarides, Mark D., Hamlin, Donald K., Wilbur, D. Scott, Balkan, Ethan R., Lin, Yukang, Miller, Brian W., Frost, Sofia.H.L., Gopal, Ajay K., Orozco, Johnnie J., Gooley, Theodore A., Laird, Kelly L., Till, Brian G., Bäck, Tom, Sandmaier, Brenda M., Pagel, John M., and Press, Oliver W.

Published
2015
Full Text
View/download PDF

35. Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor–modified T-cell therapy

Author

Gonzalez, Michael A., Bhatti, Atif M., Fitzpatrick, Kristin, Boonyaratanakornkit, Jim, Huang, Meei-Li, Campbell, Victoria L., Hecht, Jessica, Ibrahimi, Sarah, Wanner, Shera N., Green, Damian J., Maloney, David G., Gauthier, Jordan, Cowan, Andrew J., Greninger, Alexander L., Krantz, Elizabeth M., Koelle, David M., and Hill, Joshua A.

Published
2023
Full Text
View/download PDF

38. Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author

Mawad, Raya, Gooley, Ted A., Rajendran, Joseph G., Fisher, Darrell R., Gopal, Ajay K., Shields, Andrew T., Sandmaier, Brenda M., Sorror, Mohamed L., Deeg, Hans Joachim, Storb, Rainer, Green, Damian J., Maloney, David G., Appelbaum, Frederick R., Press, Oliver W., and Pagel, John M.

Published
2014
Full Text
View/download PDF

42. Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Author

Vinaud Hirayama, Alexandre, Fiorenza, Salvatore, Gauthier, Jordan, Voutsinas, Jenna M., Wu, Qian Vicky, Kimble, Erik L., Pender, Barbara S., Kirchmeier, Delaney R., Di, Henna A., Cassaday, Ryan D., Chapuis, Aude G., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2022
Full Text
View/download PDF

46. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure

Author

Banerjee, Rahul, Lynch, Ryan C, Wu, Qian Vicky, Simon, Sylvain, Ujjani, Chaitra S, Till, Brian G, Wuliji, Natalie, Gausman, Daria, Dizon, Joshua, Kwok, Mary L., Lee, Sarah S., Silbermann, Rebecca W, Medvedova, Eva, Maloney, David G., Ramos, Jorge, Shadman, Mazyar, Gauthier, Jordan, Turtle, Cameron J., Gopal, Ajay K, Green, Damian J., Riddell, Stanley R., and Cowan, Andrew J.

Published
2024
Full Text
View/download PDF

47. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering

Author

Liang, Emily C., Albittar, Aya, Portuguese, Andrew J., Huang, Jennifer J., Wuliji, Natalie, Wu, Qian, Reyes, Joseph De Los, Pin, Nikki, Torkelson, Aiko, Kirchmeier, Delaney R., Chutnik, Abigail, Pender, Barbara S., Hill, Joshua A., Banerjee, Rahul, Cowan, Andrew J., Green, Damian J., Gopal, Ajay K, Poh, Christina, Shadman, Mazyar, Hirayama, Alexandre V, Till, Brian G, Kimble, Erik L., Iovino, Lorenzo, Chapuis, Aude G., Otegbeye, Folashade, Cassaday, Ryan D., Milano, Filippo, Turtle, Cameron J., Maloney, David G., and Gauthier, Jordan

Published
2024
Full Text
View/download PDF

48. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Author

Pagel, John M., Kenoyer, Aimee L., Bäck, Tom, Hamlin, Donald K., Wilbur, D. Scott, Fisher, Darrell R., Park, Steven I., Frayo, Shani, Axtman, Amanda, Orgun, Nural, Orozco, Johnnie, Shenoi, Jaideep, Lin, Yukang, Gopal, Ajay K., Green, Damian J., Appelbaum, Frederick R., and Press, Oliver W.

Published
2011
Full Text
View/download PDF

50. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma

Author

Cassaday, Ryan D., Stevenson, Philip A., Gooley, Theodore A., Chauncey, Thomas R., Pagel, John M., Rajendran, Joseph, Till, Brian G., Philip, Mary, Orozco, Johnnie J., Bensinger, William I., Holmberg, Leona A., Shustov, Andrei R., Green, Damian J., Smith, Stephen D., Libby, Edward N., Maloney, David G., Press, Oliver W., and Gopal, Ajay K.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results